We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Test Tube Method Screens for Variant Hemoglobin

By LabMedica International staff writers
Posted on 14 Dec 2011
A ready-to-use test tube method for Hemoglobin E (HbE) has been described that can be employed as a screening test kit. More...


The novel test-tube method for HbE screening uses diethyl aminoethyl (DEAE)-cellulose resin and it is based on the principle of anion-exchange liquid chromatography.

Scientists at Chiang Mai University (Thailand) used the principle where DEAE-cellulose resin was used as the stationary phase, and glycine buffer with sodium chloride as the mobile phase. However, the method was set to be completed inside the tube instead of in an open-ended column. Equilibrated DEAE-cellulose resin is added to polystyrene tubes, followed by the addition of 2 mL eluting buffer. The tubes are capped and stored at 4 °C.

For HbE screen, packed red blood cells are mixed with a hemolysis reagent to obtain the hemolysate. An aliquot of hemolysate is added to the tube containing DEAE-cellulose resin suspension in eluting buffer, mixed vigorously and centrifuged. The color of the supernatant was then visualized after centrifugation. If the color of the supernatant was red, the result was positive, whereas a colorless or markedly pale red supernatant was negative. A positive result indicated the presence of HbE, while a negative result suggested the absence of HbE in the blood samples.

One hundred and thirteen blood samples were screened for HbE by the test tube method and by standard cellulose acetate electrophoresis (CAE). Seven of 113 samples were found to be positive for HbE by the tube method, in complete agreement with the findings from the CAE. The test-tube method is cheap and simple with no requirement of sophisticated equipment. The reagent could be stored at 4 °C for up to five months. Hemolysate samples aged up to five months were still suitable for this test.

HbE is a β-structural variant common worldwide. This Hb disorder can form a compound heterozygous state with the β-thalassemia gene, leading to life-threatening hereditary hemolytic anemia, HbE/β-thalassemia. The authors concluded that the novel test-tube method using the DEAE-cellulose resin (Sigma-Aldrich, Saint Louis, MO, USA) could be an alternative method of mass population screening for HbE, particularly in small health care facilities. The study was published online on August 23, 2011, in the International Journal of Laboratory Hematology.

Related Links:
Chiang Mai University
Sigma-Aldrich


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.